Answers are grounded in this paper and cite their sources.
Limits on access to injectable generic drugs force providers to use potentially less effective alternatives, current patients to discontinue therapy, and some new patients to receive more invasive interventions. Yet shortages of important generic drugs remain frequent.
No takes yet. Share an insight, caveat, or question.
Davies et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: